Shanghai MLWY Co., Ltd., founded in August 2013 and based in Shanghai Lingang Pujiang International Science City's advanced manufacturing base, is a high-tech innovative medical device company integrating R&D, production, and sales, focused on minimally invasive interventional therapy with independent intellectual property rights. With multi-platform energy systems including RF (radiofrequency), US (ultrasound), and PFA (pulsed field ablation), it started in cardiovascular care and continues expanding into hypertension, diabetes, COPD, heart failure, and other chronic conditions. Its core product, the Netrod® multi-electrode renal artery radiofrequency ablation system, received the FDA "Breakthrough Device" designation and NMPA innovative device expedited review, and has been approved for market. Having completed multiple funding rounds, it is a national high-tech enterprise and a specialized "little giant" SME.